DOUBLE BLIND GCSF TO PRETERM NEUTROPENIA NEONATES

双盲 GCSF 治疗早产中性粒细胞减少症新生儿

• 批准号: 6304920
• 负责人: KURT R SCHIBLER
• 金额: $ 0.16万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6304920
• 关键词: blood disorder chemotherapy; blood toxicology; clinical research; colitis; colony stimulating factor; drug screening /evaluation; granulocytopenia; human subject; human therapy evaluation; immunotherapy; neutrophil; newborn human (0-6 weeks); pediatric pharmacology; placebos; pregnancy toxemia /hypertension; premature infant human

Many premature newborn infants have difficulty manufacturing a sufficient number of white blood cells to protect them from infection. This results in a high incidence of infectious complications mary: affecting premature newborns in newborn intensive care units. This study was designed to determine if a factor that stimulates the bone marrow to make more white blood cells (granulocyte colony-stimulating factor or G-CSF) could be effective in raising the white blood cell count of premature neonates, and thereby protecting them from infectious disorders.

许多早产新生儿难以制造足够数量的白色血细胞来保护他们免受感染。这导致感染性并发症的高发生率玛丽：影响新生儿重症监护室的早产儿。 本研究旨在确定一种刺激骨髓产生更多白色血细胞的因子（粒细胞集落刺激因子或G-CSF）是否能有效提高早产儿的白色血细胞计数，从而保护他们免受感染性疾病的影响。